Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the current ratio high or low?
The current ratio of 3.81 is 61% above its 5-year average of 2.37, near the low end of its 5-year range (0.18–25.20).
As of the fiscal period ended Tuesday, June 30, 2026. 28.79% above its 12-month average of 2.96.
Reported quarterly current ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 3.81.
CURRENT RATIO
3.81
CURRENT RATIO AVG TTM
2.96
CURRENT RATIO AVG 3Y
2.29
CURRENT RATIO AVG 5Y
2.37
CURRENT RATIO AVG 10Y
N/A
CURRENT RATIO AVG 15Y
N/A
CURRENT RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+28.79%
CURRENT VS 3Y AVG
+66.36%
CURRENT VS 5Y AVG
+60.66%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
3.75
median of 874 covered companies
CURRENT VS SECTOR MEDIAN
+1.68%
vs the sector median at left
Unicycive Therapeutics, Inc.
Market Cap
$111.61M
Current Ratio
3.81
TTM Avg
2.96
3Y Avg
2.29
5Y Avg
2.37
Market Cap
$110.43M
Current Ratio
2.00
TTM Avg
1.45
3Y Avg
1.62
5Y Avg
1.71
Market Cap
$112.95M
Current Ratio
3.36
TTM Avg
3.23
3Y Avg
4.24
5Y Avg
6.08
Market Cap
$112.07M
Current Ratio
6.49
TTM Avg
6.44
3Y Avg
8.52
5Y Avg
8.53
Market Cap
$109.49M
Current Ratio
5.68
TTM Avg
5.13
3Y Avg
4.85
5Y Avg
5.20
Market Cap
$107.89M
Current Ratio
12.63
TTM Avg
12.83
3Y Avg
15.22
5Y Avg
15.22
| NAME | MARKET CAP | CURRENT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Unicycive Therapeutics, Inc. (UNCY) | $111.61M | 3.81 | 2.96 | 2.29 | 2.37 |
| Insight Molecular Diagnostics Inc. (IMDX)vs › | $110.43M | 2.00 | 1.45 | 1.62 | 1.71 |
| MaxCyte, Inc. (MXCT)vs › | $113.01M | 12.26 | 9.59 | 11.55 | 11.23 |
| Foghorn Therapeutics Inc. (FHTX)vs › | $112.95M | 3.36 | 3.23 | 4.24 | 6.08 |
| Caribou Biosciences, Inc. (CRBU)vs › | $112.07M | 6.49 | 6.44 | 8.52 | 8.53 |
| Genelux Corporation (GNLX)vs › | $113.89M | 2.39 | 3.50 | 2.69 | 1.97 |
| Lucid Diagnostics Inc. (LUCD)vs › | $114.69M | 1.33 | 1.19 | 1.50 | 3.26 |
| Apyx Medical Corporation (APYX)vs › | $109.49M | 5.68 | 5.13 | 4.85 | 5.20 |
| Aardvark Therapeutics, Inc. Common Stock (AARD)vs › | $107.89M | 12.63 | 12.83 | 15.22 | 15.22 |
| Coya Therapeutics, Inc. (COYA)vs › | $115.41M | 13.40 | 10.04 | 7.53 | 8.95 |
Current Ratio
3.81
Quick Ratio
3.81
Current Ratio = Current Assets / Current Liabilities
The current ratio measures short-term liquidity — a company's ability to cover current liabilities with current assets. Above 1.0 indicates positive working capital.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | CURRENT RATIO |
|---|---|
| 2026-06-30 | 3.81 |
| 2026-03-31 | 2.40 |
| 2025-12-31 | 2.59 |
| 2025-09-30 | 3.83 |
| 2025-06-30 | 2.18 |
| 2025-03-31 | 1.64 |
| 2024-12-31 | 1.28 |
| 2024-09-30 | 3.61 |
| 2024-06-30 | 3.37 |
| 2024-03-31 | 1.71 |
| 2023-12-31 | 0.76 |
| 2023-09-30 | 1.20 |
| 2023-06-30 | 1.42 |
| 2023-03-31 | 1.64 |
| 2022-12-31 | 0.81 |
| 2022-09-30 | 1.80 |
| 2022-06-30 | 4.43 |
| 2022-03-31 | 6.44 |
| 2021-12-31 | 8.75 |
| 2021-09-30 | 25.20 |
| 2021-06-30 | 0.18 |
| 2021-03-31 | 0.13 |
| 2020-12-31 | 0.07 |
| 2020-09-30 | 0.11 |
| 2020-06-30 | 0.02 |
| 2020-03-31 | 0.00 |
| 2019-12-31 | 0.02 |
| 2019-09-30 | 0.00 |
| 2019-06-30 | 0.00 |
| 2019-03-31 | 0.00 |
